Details for New Drug Application (NDA): 011556
✉ Email this page to a colleague
NDA 011556 describes ANTURANE, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the ANTURANE profile page.
The generic ingredient in ANTURANE is sulfinpyrazone. There are four drug master file entries for this compound. Additional details are available on the sulfinpyrazone profile page.
The generic ingredient in ANTURANE is sulfinpyrazone. There are four drug master file entries for this compound. Additional details are available on the sulfinpyrazone profile page.
Summary for 011556
| Tradename: | ANTURANE |
| Applicant: | Novartis |
| Ingredient: | sulfinpyrazone |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 011556
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
